Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Moderate to Severe Plaque Psoriasis
NCT04999839Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Started Aug 2021; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04999839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999839.